Tree-adjoining grammar

Almirall: Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost-clear skin with lebrikizumab monthly maintenance dosing at two years

Retrieved on: 
Friday, October 20, 2023
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Almirall, Lilly, Eli Lilly and Company, AD, Aes, Eli Lilly, Adherence, Conference, Maintenance, Addiction severity index, Conditional sentence, IGA, Shingles, Abstract, The New England Journal of Medicine, Conjunctivitis, British Journal of Dermatology, Atopic dermatitis, Patient, Pharmaceutical industry, Dermatology, Tree-adjoining grammar, EASI

In ADjoin, 62 percent of patients reported adverse events (AEs), most of which were mild or moderate in severity.

Key Points: 
  • In ADjoin, 62 percent of patients reported adverse events (AEs), most of which were mild or moderate in severity.
  • The most common side effects of lebrikizumab were conjunctivitis, injection site reactions and shingles (herpes zoster).
  • “Results from ADjoin reinforce the strong efficacy and safety profile of lebrikizumab seen in the other Phase 3 atopic dermatitis trials.
  • Lilly has exclusive rights for development and commercialization of lebrikizumab in the U.S. and the rest of the world outside Europe.

Blank Rome Welcomes Labor and Employment Partner Travis K. Jang-Busby in California

Retrieved on: 
Tuesday, April 4, 2023
Pepperdine University, Housing, Private, Culture, Philippine Senate Committee on Labor, Employment and Human Resources Development, Blank, IP, California Western School of Law, Veteran, Disability studies, Employment, American Bar Association Model Rules of Professional Conduct, Employment Division v. Smith, Law, Blank Rome, Labour, American Bar Association, Ridesharing, Property management, Tree-adjoining grammar

He joins from Procopio, where he was a partner in the Labor & Employment practice.

Key Points: 
  • He joins from Procopio, where he was a partner in the Labor & Employment practice.
  • Travis is the latest addition to Blank Rome’s growing California offices, which welcomed senior counsel Robert Handler in Los Angeles and partner Joseph Welch in Orange County since the start of the year.
  • “We are thrilled to welcome Travis to our growing Los Angeles and Orange County offices and nationally recognized Labor & Employment group,” said Grant Palmer , Blank Rome’s Chair and Managing Partner.
  • “Travis is a strong addition to our team as we continue to help our clients navigate California’s unique, ever-evolving employment law landscape,” said Brooke Iley , Partner and Co-Chair of Blank Rome’s Labor & Employment practice group.

Almirall: Lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study

Retrieved on: 
Tuesday, December 21, 2021
People, Lilly, TCI, Adherence, ALM, Adult, Affinity, Skin, Infection, FDA, Comparison, Eli Lilly, Mab, University Hospital (Newark, New Jersey), EASI, IGA, Conjunctivitis, Sleep, BME, Advocate, Inflammation, Medicine, Safety, Partnership, Quality of life, Adolescence, Patient, Dermatitis, Atopic dermatitis, Week, Clinical research, Company, Food, Tree-adjoining grammar, Dermatology Life Quality Index, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ageing, Flare, Almirall, Teaching hospital, AES, Dermatology, Headache, Achievement, Psoriasis Area and Severity Index, Adore, TCS, Medical device, Vaccine, Pharmaceutical industry, EU, Tralokinumab, Itch

By Week 16, the study met all primary and key secondary endpoints for patients on the lebrikizumab combination arm.

Key Points: 
  • By Week 16, the study met all primary and key secondary endpoints for patients on the lebrikizumab combination arm.
  • Andreas Pinter, Director of Clinical Research at the University Hospital in Frankfurt/Main (Germany) and one of the investigators of the ADhere trial.
  • Now, the data from ADhere also demonstrated its effect on skin clearance and itch relief as part of a combination therapy, suggesting the medicine could become a new treatment option for this immune-mediated chronic skin disease."
  • Lebrikizumab in combination with TCS also achieved all key secondary endpoints versus placebo in patients with AD, including skin improvement, itch relief, improvement in interference of itch on sleep, and quality of life.

Lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic deramatitis in two Phase 3 trials

Retrieved on: 
Monday, August 16, 2021
People, Tree-adjoining grammar, Infection, Inflammation, Medicine, Almirall, Dermatitis, AES, IGA, Fast Track, Adult, Advocate, Mab, Common, Food, Atopic dermatitis, Adherence, University, Skin, Psoriasis Area and Severity Index, EASI, Dermatology Life Quality Index, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sleep, Patient, Headache, BME, Conjunctivitis, Adolescence, Incidence, Ageing, Week, Flare, Dermatology, Adore, Quality of life, Lilly, ALM, Medical imaging, Pharmaceutical industry, Vaccine

In the top-line results from these two monotherapy studies, primary and all key secondary endpoints, including skin clearance and itch improvement, were met at Week 16.

Key Points: 
  • In the top-line results from these two monotherapy studies, primary and all key secondary endpoints, including skin clearance and itch improvement, were met at Week 16.
  • AD, also known as atopic eczema, is a chronic inflammatory skin disorder caused by skin barrier dysfunction and dysregulation of the immune response.
  • People living with AD often report symptoms of intense, persistent itch which can be so uncomfortable that it can affect sleep, daily activities and social relationships.
  • Lebrikizumab also achieved key secondary endpoints versus placebo in patients with AD, including early onset in skin clearance and itch relief, improvement in interference of itch on sleep and quality of life.